title: Clinico-roentogenologic findings in hepatocellular carcinoma fed by the right inferior phrenic artery at the initial chemoembolization.
abstract: OBJECTIVE
  The purpose of this study was to investigate factors that may predict the development of the right inferior phrenic artery (RIPA) as a feeding artery in hepatocellular carcinoma (HCC) at the initial (first session) chemoembolization.
  
  
  METHODS
  From January 1997 to June 2002, 538 patients with HCC were treated with a first session of transcatheter arterial chemoembolization (TACE). Twenty-six of these patients underwent TACE via both the Hepatic artery (HA) and RIPA at the initial TACE. We retrospectively analyzed the Child-Pugh's classification, macroscopic tumor type, location and size of the tumor, past history of intervention, complications and outcome in these 26 patients with HCC fed by the RIPA.
  
  
  RESULTS
  The incidence of HCC fed by both the HA and RIPA at the initial TACE was 4.8% (26/538 patients). No hepatic arterial occlusion or attenuation was found in any of these 26 patients. All of the tumors abutted the diaphragm and were located at the surface of the liver. All of the tumors that were larger than 5 cm in diameter protruded from the surface of the liver. Seven of the 9 patients with HCC smaller than 5 cm in diameter had a defect in the liver capsule induced by previous intervention for the treatment of a different tumor, such as hepatic resection or percutaneous ablation therapy. There were no serious complications after TACE.
  
  
  CONCLUSIONS
  The RIPA can be an extrahepatic feeding artery for HCC even at the initial TACE. A high incidence of HCC fed by the RIPA was recognized in cases in which a large tumor protruded from the surface of the liver, and when the liver capsule was damaged due to previous intervention such as hepatic resection or in ruptured HCC even at the initial TACE.
authors.affiliation: Kimura Shiro Clinic, 5-1-41 Fukushige Nishi-ku Fukuoka, 819-0022 Japan. shiro_k@d1.dion.ne.jp
authors.forename: Shiro
authors.initials: S
authors.lastname: Kimura
authors.forename: Masatoshi
authors.initials: M
authors.lastname: Okazaki
authors.forename: Hideyuki
authors.initials: H
authors.lastname: Higashihara
authors.forename: Masatora
authors.initials: M
authors.lastname: Haruno
authors.forename: Yoshimi
authors.initials: Y
authors.lastname: Nozaki
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Urakawa
authors.forename: Shinichi
authors.initials: S
authors.lastname: Kora
authors.forename: Yoshinobu
authors.initials: Y
authors.lastname: Shinagawa
authors.forename: Masanari
authors.initials: M
authors.lastname: Nonokuma
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D006528:Carcinoma, Hepatocellular / Q000098:blood supply* / Q000628:therapy*; D016461:Chemoembolization, Therapeutic / Q000379:methods*; D005260:Female; D006801:Humans; D008113:Liver Neoplasms / Q000098:blood supply* / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D012189:Retrospective Studies; D015996:Survival Rate; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome